All In Biotech

Drug Trial Radar · NCT07106827

A Study of GV20-0251 in Advanced or Refractory Solid Tumors

Single Arm Clinical Study Protocol of GV20-0251 in the Treatment of Advanced/Refractory Solid Tumors

Last checked: Nov 20, 2026Latest source record: Nov 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

10

Planned (sponsor's estimate)

Start

Sep 4, 2025

Primary completion

Jun 11, 2027

Study completion Jun 11, 2028

Sponsor

Lead sponsor
West China HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
GV20 Therapeutics
First posted
Aug 6, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single-arm, single-center study for multiple tumor indications to evaluate the safety of GV20-0251. The trial uses a 3 + 3 design and enrolls 3-6 patients in the 10 mg/kg and 20 mg/kg dose groups, respectively. The cancer types include solid tumors.

Conditions

  • HCC - Hepatocellular Carcinoma
  • Cholangiocarcinoma
  • Melanoma
  • NSCLC (Non-small Cell Lung Cancer)
  • Pancreatic Ductal Adenocarcinoma
  • HNSCC
  • Endometrial Cancer
  • Testicular Cancer

Interventions

  • GV20-0251Drug

    Increasing doses of GV20-0251 administered by intravenous (IV) infusion once every 3 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate GV20-0251 safetyTime frame: From Cycle 1 Day 1 dosing (each cycle is 21 days) until meeting the study termination criteria or 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • West China Hospital

    Chengdu, Sichuan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.